Pre­sent­ed with up­beat Alzheimer's ag­i­ta­tion da­ta, FDA sees an­oth­er 'break­through' in Ax­some's AXS-05

Ax­some Ther­a­peu­tics’ sur­prise win in a late-stage Alzheimer’s study, un­veiled just two months ago, has reg­is­tered with reg­u­la­tors. The New York-based biotech has notched a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER